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Anti-proliferative activity of the NPM1 interacting
natural product avrainvillamide in acute myeloid
leukemia
Vibeke Andresen1,8, Bjarte S Erikstein1,8, Herschel Mukherjee2, André Sulen1, Mihaela Popa3,4, Steinar Sørnes5, Håkon Reikvam5,
Kok-Ping Chan2,6, Randi Hovland7, Emmet McCormack4,5, Øystein Bruserud4,5, Andrew G Myers*,2 and Bjørn T Gjertsen*,1,4
Mutated nucleophosmin 1 (NPM1) acts as a proto-oncogene and is present in ~ 30% of patients with acute myeloid leukemia (AML).
Here we examined the in vitro and in vivo anti-leukemic activity of the NPM1 and chromosome region maintenance 1 homolog
(CRM1) interacting natural product avrainvillamide (AVA) and a fully syntetic AVA analog. The NPM1-mutated cell line OCI-AML3
and normal karyotype primary AML cells with NPM1mutations were significantly more sensitive towards AVA than cells expressing
wild-type (wt) NPM1. Furthermore, the presence of wt p53 sensitized cells toward AVA. Cells exhibiting fms-like tyrosine kinase 3
(FLT3) internal tandem duplication mutations also displayed a trend toward increased sensitivity to AVA. AVA treatment induced
nuclear retention of the NPM1 mutant protein (NPMc+) in OCI-AML3 cells and primary AML cells, caused proteasomal degradation
of NPMc+ and the nuclear export factor CRM1 and downregulated wt FLT3 protein. In addition, both AVA and its analog induced
differentiation of OCI-AML3 cells together with an increased phagocytotic activity and oxidative burst potential. Finally, the AVA
analog displayed anti-proliferative activity against subcutaneous xenografted HCT-116 and OCI-AML3 cells in mice. Our results
demonstrate that AVA displays enhanced potency against defined subsets of AML cells, suggesting that therapeutic intervention
employing AVA or related compounds may be feasible.
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Acute myeloid leukemia (AML) is a clinically and molecularly
heterogeneous disease, characterized by the accumulation of
malignant immature myeloid progenitor cells in bone marrow
and peripheral blood.1–3 Nucleophosmin 1 (NPM1) is an
essential multifunctional protein, including being a chaperone
for pre-ribosomal particles, and regulation of the activity and
stability of the tumor suppressor protein p53.4,5 NPM1 is
predominantly localized within the nucleoli and nucleoplasm
of cells, but is a nucleocytoplasmic shuttle protein, where its
nuclear export occurs through interaction with the nuclear
export factor chromosome region maintenance homolog 1
(CRM1).5–7
NPM1mutations are observed in ~ 30% of all AML patients,
and in ~ 50–60% of patients exhibiting a normal karyotype;8–12
such mutations associate with an improved prognosis,
particularly among younger patients.13–16 So far, most
of the 50 NPM1mutations identified result in the displacement
of this protein from the nucleus to the cytoplasm, consequently
named NPMc+.14,15 NPM1 mutations are considered founder
mutations in AML patients and highly stable during the course
of disease.16–18 NPM1-mutated AML blasts are characterized
by a uniquemicroRNA signature, upregulatedHOX genes and
low or absent CD34 expression.19,20
Another clinically significant mutation in AML is the internal
tandem duplication (ITD) in the juxtamembrane domain of the
fms-related tyrosine kinase 3 (FLT3) receptor; present in ~25%
of AML patients (30% in normal karyotype AML), where ~40%
of FLT3–ITD patients also comprising a NPM1mutation.12,21,22
The FLT3–ITD protein is constitutively active, resulting in
increased cellular proliferation; this mutation is associated with
resistance to chemotherapy, increased risk for disease relapse
and overall decreased survival.22
Avrainvillamide (AVA) is a prenylated indole alkaloid initially
isolated from Aspergillus ochraceus23 and has been the
subject of intense synthetic endeavors.24 This anti-
proliferative natural product was recently demonstrated to
interact with NPM1wt, NPMc+ and CRM1.25,26
In the present study, we investigated the effects of the
natural product AVA and a fully synthetic AVA analog in
leukemic cell lines, primary AML cells and in mouse xenograft
subcutanous models. AVA displayed enhanced potency
against cells expressing NPMc+, FLT3–ITD and wt p53, and
indicated efficacy in vivo.
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Results
AVA inhibits cellular proliferation and induces cell cycle
arrest and apoptosis in AML cell lines. The anti-
proliferative activity of AVA (Figure 1a) was studied in five
different AML cell lines (Table 1). The IC50 values after 24 h
treatment demonstrated that MV4-11, OCI-AML3 and
Molm-13 cells were more sensitive compared with NB4 and
HL-60 (Figure 1, Table 1). Proliferation kinetics were
investigated by treating sensitive and less-sensitive cell lines
with AVA or the biphenyl-modified AVA analog (BFA;
Figure 1a) for 6, 24 and 48 h (Figure 1c). The IC50 value
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determined by the WST-1 assay in Molm-13 cells was 14.8-
fold higher than IC50 measured by the
3H-thymidine-assay
(Figure 1d); also found in HL-60, NB4 and MV4-11 (data not
shown), suggesting that AVA affects the cellular proliferation
before metabolic activity. The AML cell lines exhibited typical
apoptotic morphology with condensed and fragmented
nuclei, as determined by Hoechst33342 staining (data not
shown) and transmission electron microscopy (Figure 1e).
OCI-AML3 cells treated with increasing concentrations of
AVA for 24 h demonstrated a rapid decrease of annexin/PI-
negative cells (live cells) at 3 μM compared with 1 μM
(Figure 1f). OCI-AML3 cells treated with 0.5 μM AVA for
24 h resulted in cell cycle G1-phase arrest (Figure 1g), also
found in MV4-11 cells (Supplementary Figure 1).
AVA displays anti-proliferative activity that associates
with NPM1 and FLT3 mutational status in AML patient
cells. AML patient samples (Supplementary Table 1) were
treated for 24 h with 10 nM–100 μM AVA (Figure 2a; 1, 10 and
30 μM presented). We observed a highly variable anti-
proliferative response with a median IC50 value of 7.1 μΜ
(Supplementary Table 2; Supplementary Figure 2a), similarly
using the WST-1 assay (Figure 2b). Primary AML patient
samples (Supplementary Table 3) incubated for 7 days with
FLT3 ligand, GM-CSF and SCF also responded highly variable
(Figure 2c). Some of the primary AML cells showed increased
proliferation at lower doses a phenomena also described for
other anti-cancer drugs.27,28 No significant differences in the
mean following AVA or BFA treatment analog in 35 AML patient
samples were found by the WST-1 assay (Figure 2d), or by the
3H-thymidine-assay (data not shown). We then investigated if
AVA displayed enhanced potency toward malignant cells
compared with healthy umbilical cord blood CD34+ cells from
three donors (Figure 2e) and healthy PBMCs from five donors
(Supplementary Figures 2b,c). If the CD34+ cells represented a
homogeneous AVA response, one sensitive and one less-
sensitive group of AML cells were observed. However, most
likely attributed to the heterogeneous response by the primary
AML cells, no significant differences were observed (Figure 2e).
Healthy PBMCs demonstrated a homogenous response and
appeared more sensitive compared with the CD34+ cells with
an IC50 value of o3 μM (Supplementary Figures 2b, c).
To identify sensitive AML patient-derived cells, we sought to
correlate the effects of AVAwith biological characteristics. AVA
treatment inhibited AML-M5 to a greater extent than AML-M1
(Supplementary Figure 3a). Similar results were obtained in
the 7-days assay using 1 μMAVA (P= 0.041, data not shown).
We also observed an association between AVA sensitivity and
expression levels of CD15, CD14 and CD11c (Supplementary
Figures 3b–d). As AML-M5 cells exhibit a more mature
phenotype and presumably higher basal proliferation
activity,29 we investigated proliferation and AVA sensitivity.
Indeed, we found a significant association between prolifera-
tion rates and proliferation inhibition in AML patient cells
(Supplementary Figure 3e). We did not, however, find
significant differences in basal proliferation rates between
AML-M1 and AML-M5 patient cells or cells with high or low
CD15 expression (data not shown), indicating that factors
besides proliferation rate play a sensitizing role toward AVA.
Mutations in the NPM1 and FLT3 genes constitute the
largest groups of genetic changes in AML patients with normal
karyotype.12 NPM1 mutations are primarily associated with
AML-M4 and AML-M519,30 and almost always result in a
change of reading frame in the C-terminal domain of theNPM1
mutant and a cytoplasmic localization in AML cells.14 As the
NPM1-mutated OCI-AML331 cell line demonstrated enhanced
sensitivity towards AVA that interacts with the C-terminal
domain of both wild-type (wt) and mutant NPM1,25,26 and the
BFA with the C-terminal of NPM1 (personal communication;
https://dash.harvard.edu/handle/1/17467289); we investi-
gated if NPM1 mutational status was associated with AVA
sensitivity. We studied the anti-proliferative effects of AVA in 12
normal karyotype AML patient samples. Cells bearing
NPM1 mutations were significantly more sensitive toward
AVA than cells expressing NPM1wt only (Figure 2f).
As four of the NPMc+ patient samples also contained an
FLT3–ITDmutation, we sought to determine if FLT3mutational
status similarly affected AVA sensitivity. Significance were still
observed after including two additional normal karyotype
AML patient samples with FLT3–ITD and NPM1wt and cells
with FLT3–ITD mutations showed a distinct trend toward
Figure 1 Effects of avrainvillamide on AML cell lines. (a) Structure of avrainvillamide (AVA) and AVA biphenyl analog (BFA). (b) NB4, HL-60, MV4-11, OCI-AML3 and Molm-
13 cells were incubated with AVA (10 nM–30 μM) for 24 h, (n= 3–7), and proliferation was determined by 3H-thymidine incorporation. For all cell proliferation experiments, cells
were incubated with 3H-thymidine for 6 h immediately before scintillation counting. Results represent the mean±S.E.M. of the values relative to vehicle controls. (c) HL-60 and
MV4-11 cells were treated for 6, 24 or 48 h with 1 μM AVA or its BFA (n= 3–4), then proliferation was determined by 3H-thymidine incorporation. (d) Molm-13 cells were treated
with varying concentrations of AVA (10 nM–30 μM) for 24 h. The cells were either incubated with 3H-thymidine or resazurin for the final 4 h before scintillation counting or
assessment of fluorescence emission, respectively. Results indicate the mean of the values relative to vehicle controls (n= 3–4). Triangles and squares represent measured rates
of proliferation and metabolic activity, respectively. (e) HL-60 cells were treated with DMSO (CTR) or 3 μM AVA for 24 h and examined by transmission electron microscopy (scale
bar, 2 μm). (f) Histogram displayed for OCI-AML3 cells treated with DMSO (CTR) or 1.0, 3.0 and 10 μM AVA for 24 h, stained with annexinV and propidium (PI) and analyzed by
flow cytometry. AnnexinV/PI-negative cells are graphed as live cells normalized to CTR for all concentrations of AVA mean± S.D. (n= 3). (g) Cell cycle analyses of OCI-AML3
cells treated for 24 h with 0.5 μM AVA following fixation, PI staining and flow cytometry analysis. Representative histogram with G1, S and G2/M is shown and the subG1, G1, S
and G2/M phases are graphed using mean±S.D. (n = 5, ***Po0.001). For all flow cytometric analyses least 10 000 events per sample were acquired
Table 1 Molecular characteristics and IC50 values of AML cell lines
Cell line FAB NPM1 FLT3 p53 IC50 (nM)
NB4 M3 wt wt Mut 1100
HL-60 M2 wt wt Del 643
MV4-11 M5 wt ITD wt 116
OCI-AML3 M4 Mut A wt wt 112
Molm-13 M5 wt ITD wt 78
Abbreviations: Del, deletion; FAB, French-American-British classification;
FLT3= fms-related tyrosine kinase 3; ITD, internal tandem duplication; Mut,
mutant; wt, wild-type
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Figure 2 Effects of avrainvillamide on primary AML patient cells. Primary AML cells were incubated with avrainvillamide (AVA; 10 nM–300 μM) for 24 h and proliferation
assayed by (a) 3H-thymidine incorporation or (b) metabolic activity determined by the WST-1 assay. Results are shown for 1.0, 10 and 30 μM AVA treatment. (c) Primary AML
cells were incubated with a cytokine cocktail (FLT3 ligand, SCF and GM-CSF) containing DMSO or AVA (3 μM) for 7 days. Proliferation was assayed by 3H-thymidine
incorporation. Circles represent the mean values relative to vehicle controls; horizontal bar indicates the median of all 52 values. (d) Primary cells from 35 AML patients were
treated with AVA or BFA (10 μM) for 24 h. Dots or squares represent the mean values relative to vehicle controls compared with untreated controls. Horizontal bars represent the
median values. (e) Primary cells from 23 AML patients and three umbilical cord CD34+ blood samples were treated with AVA (3 μM) for 24 h. Cells were stained with annexinV/PI
and analyzed by flow cytometry. Circles represent the mean values relative to vehicle controls. Horizontal bars indicate the median values. (f) Primary AML cells with normal
karyotype and either wild-type NPM1 (wt, n= 7) or mutated NPM1 (mut, n= 5) were treated with AVA (0.1, 1.0, 10 and 30 μM) for 24 h and assayed by 3H-thymidine
incorporation. Symbols represent the mean values relative to vehicle controls. Wt NPM1, wt FLT3 (●), mutant NPM1, FLT3–ITD (○) and mutant NPM1, wt FLT3(▲). Horizontal
bars represent the median values (*Po0.05). (g) The same patient samples from f, including two additional FLT3–ITD, wt NPM1 AML patient samples (■) were incubated with
30 μM AVA and assayed by 3H-thymidine incorporation. Wt NPM1, wt FLT3 (●), mutant NPM1, FLT3–ITD (○) and mutant NPM1, wt FLT3(▲). Horizontal bars represent the
median values (*Po0.05)
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significance (Figures 2g; P=0.073) suggesting an
AVA-sensitizing role for FLT3–ITD mutations.
p53 sensitizes AML cells toward AVA treatment. As
NPM1 influences the activity and stability of the p53
protein5 and given the association between TP53 mutations,
p53 protein expression level, isoform profile and long-term
survival in AML patients,32–34 we examined the connection
between AVA and p53. AVA induces p53 expression in
certain cancer cell lines;26 furthermore, wt p53 AML cell lines
Figure 3 The presence of wild-type p53 sensitizes cells towards avrainvillamide treatment. (a) Immunoblots showing p53, p21 and actin (loading control) expression levels in
OCI-AML3 and MV4-11 cells treated with avrainvillamide (AVA; 0, 0.5 and 1.0 μM) for 24 h. (b) Flow cytometry analysis of p53 expression in OCI-AML3 and MV4-11 cells treated
with DMSO (CTR) or 0.5 μM AVA for 24 h. Representative results from a single experiment are shown. US, unstained. (c) Flow cytometric median fluorescence intensity (MFI)
quantification of p53 (unstained subtracted, n= 3) in OCI-AML3 and MV4-11 cells. Results represent mean± S.E.M. (d) Molm-13 cells were transduced with empty vector (CTR)
or shp53 then immunoblotted for p53 expression. Actin is shown as a loading control. (e) Flow cytometry analyses of p53 expression levels in non-irradiated and gamma-
irradiated Molm-13 cells transduced with empty vector (CTR) or shp53. (f) Proliferation of Molm-13 cells following transduction with empty vector (CTR) or shp53 and treatment
with AVA (0.01 (.01), 0.03 (.03), 0.1, 0.3 or 1 μM) for 24 h. Results represent mean±S.E.M. of the values relative to vehicle controls (n= 4; *Po0.05). HEK293 cells were
transfected with (g) NPM1wt-ECGFP or (h) NPMc+-ECGFP, and treated with DMSO (CTR) or AVA (0.5 μM) for 24 h or LMB (10 nM) for 3 h. Cells were fixed and analyzed by
fluorescence microscopy. All transfection experiments were conducted at least three times; representative images are shown. Arrows indicate localization of NPM1wt and NPMc+
(DAPI indicates nuclei; scale bar, 10 μm)
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were more sensitive compared with p53 null or p53 mutated
(Figure 1b; Table 1). Subsequent immunoblot and flow
cytometry experiments revealed that AVA treatment
increased p53 and p21 protein levels in OCI-AML3 and
MV4-11 cells (Figures 3a–c). To investigate the potential
roles of p53 in AVA-induced anti-proliferation, Molm-13 cells
transduced with either short hairpin RNA against p53 (shp53)
or empty control vector (CTR) were studied.35 Cells with
shp53 showed ~70% reduced p53 expression and p53
activation after gamma-irradiation compared with CTR cells
(Figures 3d and e). The shp53 cells were significantly less
sensitive toward AVA compared with CTR cells (Figure 3f),
demonstrating an AVA-sensitizing role of p53.
We then investigated whether AVA influenced the
subcellular localization and expression levels of wt NPM1
and NPMc+ proteins. As a positive control, we included the
CRM1 inhibitor, leptomycin B (LMB), causing nuclear retention
of NPMc+ proteins.36 HEK293 cells transfected with NPM1wt-
ECGFP or NPMc+-ECGFP plasmids were treated with
DMSO, AVA or LMB. The NPM1wt-ECGFP protein localized
predominantly within the nuclei and nucleolus of control cells
and no change was observed in treated cells (Figure 3g). On
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the other hand, the NPMc+-ECGFP protein localized to the
cytoplasm of control cells, but relocated to the nuclei after AVA
or LMB treatment (Figure 3h).
AVA causes nuclear retention and downregulation of
NPMc+ accompanied by decreased expression of CRM1
and FLT3 in AML cells. We next examined the effect of AVA
on endogenous expression of NPMc+ in OCI-AML3 cells by
immunostaining using NPM1wt- and NPMc+-specific anti-
bodies. NPM1wt concentrated in the nucleoli and nucleo-
plasm of control cells, but was also observed in the
cytoplasm, presumably due to hetero-oligomer formation,37
whereas NPMc+ predominantly localized to the cytoplasm
(Figure 4a). Following AVA and LMB treatment, NPM1wt
exclusively localized to the nucleoli and nucleoplasm,
whereas NPMc+ re-localized from the cytoplasm to the
nucleus (Figure 4a). The effect of AVA on cells expressing
NPM1wt only was assessed in MV4-11 cells. RanBP1,
another nucleocytoplasmic shuttle protein and CRM1 inter-
acting protein, was used as a potential positive control for the
nuclear export inhibiting the effect of AVA. The localization of
NPM1wt and RanBP1 was influenced by 1 μM AVA treat-
ment, resulting in nuclear localization of RanBP1 and in
addition to nucleolar, NPM1wt was found in nucleoplasmic
dots (Figure 4b), indicating a connection between cell cycle
arrest, p53 and nucleolar stress, as reported previously.38
Quantification of NPM1wt and NPMc+ protein levels
following AVA treatment, using flow cytometry, revealed a
significant reduction of NPMc+ in OCI-AML3 cells (Figures 4c
and d). AVA treatment also reduced NPM1wt levels in OCI-
AML3 cells; however, a similar decrease was not observed in
MV4-11 cells (Figures 4c and d). Specificity of the anti-NPM1
antibodies was demonstrated by immunoblotting (Figure 4e),
before the flow cytometry results were confirmed, except the
reduction of NPM1wt in OCI-AML3 cells that appeared less
pronounced by immunoblotting (Figure 4f).
As the nuclear export of NPMc+ and NPM1wt proteins is
mediated by CRM1 and AVA interacts with NPM1 and
CRM1,25 we investigated the effects of AVA on CRM1 activity
and expression levels. Following 0.5 μM AVA RanBP1 was
retained in the nucleus of OCI-AML3 cells (data not shown),
in agreement with the previous results in the MV4-11 cells and
in the non-leukemic cells HCT-116.25 Furthermore, we
observed CRM1 downregulation in OCI-AML3 and MV4-11
cells by flow cytometry and this was confirmed by
immunoblotting, most prominent at 1 μM concentration for
MV4-11 cells (Figures 4g–i).
Recently, FLT3 downregulation has been reported upon
treatment with a CRM1 inhibitor39 and we therefore assessed
the effects of AVA on FLT3 expression and localization in
OCI-AML3 cells andMV4-11 cells. AVA reduced FLT3 levels in
OCI-AML3 and FLT3–ITD expression in MV4-11 cells
(at 1 μM) as determined by immunoblotting (Figure 4j). No
change in subcellular localization was found for FLT3wt
protein in OCI-AML3 cells, following AVA treatment (data not
shown). When OCI-AML3 cells were co-treated with AVA and
the proteasome inhibitor bortezomib, the AVA-induced CRM1
and NPMc+ degradation was reversed, but not the FLT3
degradation (Figures 4k and l).
We further studied the effects of AVA on four primary AML
samples with normal karyotype, wt FLT3 and mutated NPM1
(Supplementary Table 4). The AML patient samples were
treated with DMSO, AVA or LMB then analyzed by immuno-
fluorescence, immunoblotting and flow cytometry (Figure 5). In
contrast to our observations in the OCI-AML3 cell line, NPMc+
did not exclusively accumulate within the cytoplasm of patient-
derived AML blasts. Rather, the NPMc+ protein localized to
the cytoplasm, diffusely throughout the nucleoplasm and in
nucleoplasmic speckles. The NPMc+ protein was apparently
excluded from nucleoli, contrasting the predominant nucleolar
localization of the NPM1wt protein (Figure 5a). Both AVA and
LMB treatment resulted in the reduced cytoplasmic
NPMc+, and a nucleoplasmic localization was observed,
whereas no change in subcellular localization was found for
NPM1wt with any treatment (Figure 5a). Immunoblotting
revealed that all four AVA-treated patient samples showed
reductions in NPMc+, FLT3 and CRM1 protein levels,
increased protein levels of p53 and no apparent change in
NPM1wt levels (Figure 5b). Flow cytometry confirmed
reduced levels of NPMc+ and CRM1 (Figures 5c–f) and
p53 increase (data not shown). Taken together our data
demonstrate that AVA influences the subcellular localization of
NPM1wt and NPMc+ proteins, and modulates protein levels of
NPMc+, CRM1, FLT3 and p53 in AML cell lines and primary
AML cells.
Figure 4 Avrainvillamide treatment causes nuclear retention of NPMc+ proteins and reduced expression levels of NPMc+, CRM1 and FLT3 proteins in AML cell lines. (a)
OCI-AML3 cells were treated DMSO (CTR) or avrainvillamide (AVA; 0.5 μM) for 24 h or LMB (10 nM) for 3 h, then cytospun onto coverslips, fixed, and stained with NPM1wt- and
NPMc+-specific antibodies. (b) MV4-11 cells were treated with DMSO (CTR) or AVA (0.5 μM and 1.0 μM), cytospun onto coverslips, fixed, and stained with NPM1wt and RanBP1
antibodies. All immunofluorescence experiments were conducted at least three times; representative images are shown and arrows indicate described localization and zoomed
cells for MV4-11. (DAPI indicates nuclei; scale bar, 10 μm). (c) OCI-AML3 and MV4-11 cells were treated with AVA (0.5 μM) for 24 h and analyzed by flow cytometry using
specific antibodies against NPMc+ and NPM1wt as indicated. Results from representative experiments are shown. (Sec= secondary antibody only). (d) Flow cytometry median
fluorescence intensity (MFI) quantification of NPM1 expression levels in OCI-AML3 and MV4-11 cells. Results represent the median±S.E.M. of three independent experiments
(**Po0.01). (e) Validation of NPM1 antibody specificity by immunoblotting using cell lysates of OCI-AML3 (OCI) and MV4-11 (MV4) incubated with NPM1wt and NPMc+
antibodies. (f) Immunoblots for NPMc+ expression in OCI-AML3 cells and NPM1wt expression in OCI-AML3 and MV4-11 cells incubated with AVA (0.5 μM) for 24 h. (g) CRM1
expression as determined by flow cytometry in OCI-AML3 and MV4-11 cells after incubation with AVA (0.5 μM) for 24 h, representative image is shown and (h) flow cytometry
MFI quantification of the median± S.E.M. of three independent experiments relative to control (n= 3, **Po0.01; Sec= secondary antibody only). (i) CRM1 expression after
incubation with AVA (0.5 μM; OCI-AML3, 1.0 μM; MV4-11) for 24 h, as determined by immunoblotting. (j) FLT3 expression after incubation with AVA (0.5 μM; OCI-AML3, 1.0 μM;
MV4-11) for 24 h, as determined by immunoblotting. (k and l) OCI-AML3 cells were treated with either DMSO (CTR), AVA alone (0.5 μM, 24 h), AVA (0.5 μM, 24 h) with
bortezomib (Comb; 50 nM, final 8 h) or bortezomib (Brz; 50 nM, final 8 h) alone and then immunoblotted for NPMc+, CRM1, FLT3 and NPM1wt. Actin and CoxIV were used as
loading controls for the immunoblots
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AVA and the AVA analog induce cellular differentiation,
increase phagocytosis and ROS capacity. As compounds
interacting with CRM1 or NPM1 induce cellular
differentiation,39,40 we sought to determine if AVA caused
differentiation. OCI-AML3 cells were treated for 72 h with
AVA, BFA or the CRM1 inhibitor KPT-330, then subjected to
flow cytometric analysis for expression levels of common
myeloid differentiation markers (CD11b, CD14, CD86,
CD163, HLA-DR, CD16 and CD40). All three compounds
significantly induced CD11b expression relative to controls;
furthermore, BFA increased CD86 and CD14 expression,
whereas KPT-330 significantly induced CD163, CD86 and
CD14 (Figure 6a; Supplementary Figure 4). BFA induced an
increase in CD86 and CD14 expression, not observed for
AVA alone, which could indicate a functional difference.
No changes in expression were observed for
HLA-DR, CD16 or CD40 under any treatment conditions.
In addition, flow cytometric forward-side scatter analysis
revealed an increase in cellular size upon exposure to all three
compounds; this was verified by May-Grünwald-Giemsa
staining demonstrating larger cells with increased cytoplasm
(Figure 6b). As CD11b expression was increased, we next
assessed the phagocytic potential of these cells without and
with human serum opsonisation in a fluorescent phagocytosis
assay. All treatments resulted in increased number of
phagocytic cells after opsonisation as compared with the
control cells (which themselves also demonstrated phagocytic
activity), indicating IgG- or complement-mediated binding of
bacteria to the cells (Figure 6c). Fluorescence microscopy
indicated increased number of bacteria associated with
treated cells (Figure 6d). Addition of trypan blue to quench
fixed extracellular bacteria, but not the internalized, revealed
that the treated, differentiated cells contained increased
degree of internalized bacteria relative to undifferentiated
control cells (data not shown). We next investigated the
oxidative burst activity by adding a reactive oxygen species
(ROS) probe to this system. Treated cells exhibited higher
oxidative capacity compared with control cells; however, these
results were found to be insensitive to opsonisation of the
Gram-positive bacteria. Notably, the same result was found
even without bacteria, indicating that the differentiated cells
exhibited higher basal oxidative capacity (data not shown). To
further investigate this, OCI-AML3 cells were treated for 72 h
and evaluated using a nitroblue tetrazolium (NBT) reduction
assay where ROS reaction with NBT results in a dark blue
precipitate. Following phorbol 12-myristate 13-acetate (PMA)
stimulation, treated and differentiated cells more effectively
generated ROS compared with control cells, providing
evidence for increased oxidative burst capacity of treated
cells (Figures 6e and f).
AVA analog treatment reduces tumor growth in vivo. We
first assessed the in vivo activity of 2 mg/kg BFA in BALB/c
nude mice. Snapshot pharmacokinetics (PKs) revealed an
increase in the accumulation of BFA in plasma and in
subcutaneous HCT-116 xenografted tumors 1 h after admin-
istration intraperitoneal (i.p.) injection. After 6 h, BFA plasma
and tumor concentrations decreased to ~ 50%, indicating a
need for a twice a daily (BID) administration (Figure 7a). An
initial toxicity screen, based on the lack of significant weight
loss, revealed that 4 mg/kg BFA (BID, i.p.) was well tolerated;
however, two of six animals died when dosing was increased
to 10 mg/kg BID (data not shown). For tumor growth inhibition
experiments, BALB/c nude mice were subcutaneously
implanted with HCT-116 cells; as we previously investigated
AVA effect on this cell line.25 When tumors reached
~100 mm3, treatment was initiated for 14 days with vehicle
control, BFA (4 mg/kg BID, i.p.) or cyclophosphamide (CTX,
20 mg/kg BID, i.p.). Both BFA and CTX treatment resulted in a
significant tumor growth inhibition (Figure 7b), although also
exhibiting low toxicity as measured by changes of relative
body weight. CTX inhibited the tumor growth to a greater
extent than treatment with BFA (Figure 7b).
Finally, we investigated the efficacy of BFA against a
xenograft OCI-AML3 tumor model in NOD/SCID IL2rγnull
(NSG) mice.41 An initial toxicity screen revealed that 4 mg/kg
BFA (BID, i.p.) was well tolerated, whereas higher concentra-
tions were toxic (data not shown). Thus, NSG mice were
injected subcutaneously with OCI-AML3 cells and treatment
was initiated when tumors reached ~100mm3. Vehicle control
or BFA (4 mg/kg, BID, i.p.) were administered on a 5-days on,
2-days off schedule for 2 weeks. BFA-treated animals showed
slightly reduced tumor growth rates as compared with vehicle-
treated animals and no significant weight loss was observed
during the treatment period (Figure 7c). Subcutaneous tumors
were collected at euthanization and cells were cryopreserved.
Tumor cells of control (n=3) and treated (n=3) mice were
investigated by flow cytometric analysis for expression levels of
common myeloid differentiation markers and CD11b expres-
sion was significantly increased in the tumor cells from the
BFA-treated mice (Figure 7d). However, no increased ROS
capacity was found in any of the tumor-derived cells following
the NBT reduction assay (data not shown). Also, no change
was found in cellular morphology after May-Grünwald-Giemsa
staining, NPMc+ localization after immunostaining, or CRM1 or
FLT3 protein expression by immunoblotting (data not shown).
Discussion
AML cellswith NPM1mutations exhibited increased sensitivity
toward AVA treatment, a trend also observed in AML cells with
FLT3–ITD mutations. The last observation is of particular
interest, as 40% of AML patients exhibiting NPM1 mutations
concurrently contain FLT3–ITD mutations and this is asso-
ciated with early relapse and poorer prognosis compared with
AML patients with NPM1 mutations only.12,21
AVA-induced G1-phase cell cycle arrest in AML cells
consistent with an increase in p53 and p21 levels
demonstrated previously to directly or indirectly induce cell
cycle arrest.42 Although the presence of wt p53-sensitized
AML cells toward AVA, higher doses inhibited proliferation of
p53-reduced, p53-null or p53-mutated cells. TP53 mutations
have been reported mutually exclusive with NPM1 mutation
and FLT3–ITD,43–45 underscoring the probability for AVA
sensitivity in AML patients with NPM1 and FLT3–ITD.
We additionally found that AVA treatment resulted in
proteasome-mediated degradation of NPMc+, CRM1 and a
reduction of FLT3 through an unknown mechanism. Interest-
ingly, siRNA-mediated reduction of wt NPM1 in OCI-AML3
cells has previously been reported to reduce FLT3 and NPMc+
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levels, and cause increased cellular sensitivity toward retinoic
acid and cytarabine, suggesting a connection between NPM1
and FLT3 regulation.40
AVA did not affect the subcellular localization of the
NPM1wt-ECGFP protein in transfected HEK293 cells; how-
ever, the NPMc+-ECGFP protein was retained in the nuclei.
Figure 5 Avrainvillamide treatment decreases expression levels of NPMc+, CRM1 and FLT3 proteins in AML primary patient cells. (a) Four primary AML samples
(Supplementary Table 5) were treated with DMSO (CTR), avrainvillamide (AVA; 0.5 μM and 1.0 μM) for 24 h or LMB (10 nM) for 3 h. Cells were then cytospun onto coverslips,
fixed and stained using NPMc+- and NPM1wt-specific antibodies. Results from one representative patient sample (P46) are shown (DAPI indicates nuclei; scale bar, 10 μm). (b)
AML patient samples (Supplementary Table 4) were treated with DMSO (CTR), AVA (0.5 μM) for 24 h or LMB (10 nM) for 3 h, lysed and immunoblotted for CRM1, NPMc+, p53,
FLT3, NPM1wt and CoxIV expression (loading control). (c–f) AML patient cells (Supplementary Table 5) were treated with DMSO (CTR) or AVA (0.5 μM and 1.0 μM) for 24 h,
fixed and analyzed by multiplexed flow cytometry for CRM1 (c), and NPMc+ (d) expression by gating on living cells (stained with an aminoreactive dye before permeabilization),
specifically analyzing AML blasts, as determined by the use of anti-CD45- (negative) and anti-CD33- (positive) specific antibodies. Results from one representative patient sample
are shown. US, unstained. (e) Flow cytometric median fluorescence intensity (MFI) quantification of CRM1 and (f) NPMc+ expression in the four primary AML patient samples,
results represent mean± S.E.M. Comparisons between treated and control samples were conducted using a paired Student’s t-test (*Po0.05, **Po0.01)
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Similarly, AVA treatment did not affect the localization of wt
NPM1 in OCI-AML3 cells or primary AML blasts, but induced
nuclear retention of the cytoplasmic NPMc+ protein. AVA also
induced nuclear retention of other CRM1-dependent cargo
proteins, such as RanBP1, supporting a direct interaction
between AVA and CRM1.25
The selective CRM1 inhibitor LMB prevents the nuclear
export of CRM1 cargo proteins by covalent modification of
CRM1 Cys528.46 However, LMB and other CRM1 inhibitors
have been demonstrated too toxic for use in vivo.46 Recently,
novel orally available, selective inhibitors of nuclear export
have been developed,39,47 which also interact with Cys528 of
CRM1, inhibit nuclear export of CRM1 cargo proteins
and exhibit anti-cancer activity in vitro and in vivo models of
leukemia and lymphoma.39,48–51 Interestingly, AML cell lines
and primary AML cells treated with the CRM1 inhibitor
KPT-185 shared several phenotypic similarities with
AVA-treated cells, including induction of p53 and down-
regulation of both FLT3 and CRM1.39 In addition, we found
that AVA and the AVA analog (as well as KPT-330) induced
Figure 6 Avrainvillamide and BFA induce differentiation, increase phagocytosis and oxidative burst of OCI-AML3 cells. (a) OCI-AML3 cells were treated for 72 h with DMSO
(CTR), AVA (0.5 μM), BFA (0.5 μM) or KPT-330 (0.1 μM) before live cells were stained and analyzed by flow cytometry for CD163, CD86, CD14 and CD11b expression by gating
on living cells. Fold changes (mean±S.D.) relative to controls are shown (n= 3). Comparisons between treated and control samples were conducted using an unpaired Student’s
t-test (***Po0.001). (b) OCI-AML3 cells were treated for 72 h with DMSO (CTR), avrainvillamide (AVA; 0.5 μM), BFA (0.5 μM) or KPT-330 (0.1 μM) and analyzed by flow
cytometry and cytospun and stained with May-Grunwald-Giemsa before analyzed by microscopy (Zeiss axio Observer A1) using a × 40 objective lens. A representative
histogram for AVA-treated cells is shown to the left and representative May-Grunwald-Giemsa stained images are shown (n= 3). Scale bars, 10 μm. (c) OCI-AML3 cells treated
with DMSO (CTR), AVA (0.5 μM), BFA or KPT-330 for 72 h followed by phagocytosis assay with opsonization of fluorescent bacteria. Quantification of increase in phagocytotic
cells compared with CTR (n= 3), results represent mean± S.D. (***Po0.001). (d) Localization of fluorescently labeled bacteria in 72 h BFA-treated OCI-AML3 cells stained with
DAPI. Images were captured using Zeiss Axio ObserverZ1, × 63 oil objective. Scale bars, 10 μm. (e) OCI-AML3 cells were treated with DMSO (CTR), AVA (0.5 μM), BFA
(0.5 μM) or KPT-330 (0.1 μM) for 72 h before 2 × 105 cells were incubated with nitroblue tetrazolium (NTB—reaction with ROS produces a dark blue color) and stimulated with
PMA for 30 min at 37 °C. Cells were cytospun and counterstained with Safranin O and images were captured using Zeiss Axio Observer A1, × 10 objective (n= 3). Scale bars,
50 μm. (f) BFA-treated cells from (e) were stained with additional DAPI. Images were captured using Zeiss Axio Observer A1, × 40 objective. Scale bars, 20 μm
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morphological and immunophenotypic differentiation of
OCI-AML3 cells. The effects of AVA on cellular differentiation
are likely directly linked to the observed increase in p53
expression, as reported for KPT-185.39 We further demon-
strated the cellular functionality associated with the
differentiated cells, such as increased oxidative burst capacity
and phagocytosis. This clearly unveils the important thera-
peutic potential hidden in the discovery of novel compounds
with the capacity to induce differentiation in AML cells.52
Finally, we found a modest anti-proliferative effect of the
AVA analog in vivo. However, calculation of AVA analog
concentration in plasma and tumor based on the snap-PK
(Supplementary Table 5) revealed that the optimal in vitro
concentrations most likely are not achievable in vivo and this
could explain the modest anti-proliferative effects found in the
two in vivo mouse models. Also, healthy human PBMCs
showed sensitivity toward AVA at doses of 3 μM and 10 μM
(Supplementary Figures 2b and c) that could explain the
Figure 7 BFA treatment reduces the tumor growth in xenograft mouse models. (a) Snap-PK for 2 mg/kg BFA concentration (ng/ml) in plasma and tumor of BALB/c nude mice
implanted subcutaneously with HCT-116 cells (n= 2) measured after 1, 6 and 24 h. (b) BALB/c nude mice xenografted subcutaneously with HCT-116 cells were treated BID i.p.,
when tumor sizes reached ~ 100 mm3 with vehicle control (n= 6), BFA 4 mg/kg (n= 6) or CTX 20 mg/kg (n= 6) as indicated for 14 days. The tumor sizes were measured and
relative weight change (%) calculated. Comparisons (mean±S.E.M.) between tumors from treated and control mice were conducted using an unpaired Student’s t-test (*Po0.05,
**Po0.01). (c) NSGmice xenografted subcutaneously with OCI-AML3 cells were treated BID i.p., when tumor sizes reached ~ 100 mm3 with vehicle control (n= 3) or BFA 4 mg/kg
(n= 3), as indicated and the tumor sizes were measured and relative weight change (%) calculated. Comparisons (mean±S.E.M.) between tumors from treated and control mice
were conducted using an unpaired Student’s t-test (*Po0.05). (d) Live tumor-derived cells were stained and analyzed by flow cytometry for CD11b expression (median
fluorescence intensity (MFI)) by gating on living cells (PI or TO-PROIII negative). Representative histogram is shown at the left. Fold changes (mean±S.D.) relative to controls
(CTR) are shown (n= 3 tumors). Comparisons between control and treated tumor-derived cells were conducted using an unpaired Student’s t-test (**Po0.01). US, unstained
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toxicity observed with doses 44 mg/kg in the mice. The
reported CRM1 inhibitors have been shown to sensitize
malignant cells to other cytotoxic agents,53 thus further
supporting exploration of AVA in combination therapies.
In conclusion, we report functional and biologic activities of
AVA, and an AVA analog in AML cells and in vivo. AVA and its
existing analogs may thus represent a novel therapeutic
strategy capable of targeting defined subsets of AML patients
through their ability to interact with both NPM1 and CRM1, and
possibly leukemia inititation cells as recently demonstrated for
selinexor (KPT-330).54 We believe that further exploration of
this family of compounds will lead to the identification of
candidate molecules with improved physicochemical and
PK properties for further evaluation in preclinical contexts.
Materials and Methods
Cell lines and primary human samples. HL-60, NB4, MV4-11, Molm-13,
HEK293, HCT-116 (ATCC, Manassas, VA, USA) and OCI-AML3 (DSMZ,
Braunschweig, Germany) cells were grown according to the provider’s instructions.
Primary AML cells and CD34+ umbilical cord blood cells were cultured in StemSpan
SFEM medium (Stem Cell Technologies Inc., Vancouver, BC, Canada).
The study was conducted in accordance with the Declaration of Helsinki and
approved by the local Ethics Committee (Regional Ethics Committee West, University
of Bergen, Bergen, Norway). Blood samples from consecutively diagnosed AML
patients with high peripheral blood blast counts (47 × 109/l ) were collected after
informed consent and blood samples were processed by density gradient separation
with 495% leukemic blasts for biobanking as previously described.55
Umbilical cord blood was collected from healthy newborns with subsequent
CD34+ cell isolation from PBMCs using the CD34 MicroBead Kit (Miltenyi Biotec,
Bergisch Gladbach, Germany).
PBMCs were acquired from random healthy blood donors at Department of
Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen,
Norway.
Reagents, antibodies and plasmids. AVA (C26H27N3O4, MW 445.51;
AVA) and the BFA (C29H29N3O3, M.W. 467.56; BFA) were synthesized as previously
described.23,26
LMB was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA) and
bortezomib from Millenium Pharmaceuticals (Cambridge, MA, USA).
NPM1 antibodies: anti-wt-NPM136 (Invitrogen, Waltham, MA, USA, FC-61991);
anti-NPM1mutantA (Abnova, Taipei City, Taiwan). The following antibodies were all
purchased from Santa Cruz Biotechnology, Dallas, TX, USA: anti-CRM1 (H-300),
anti-FLT3 (S-18), anti-p53 (Bp53-12) and anti-β-actin (sc-47778); from Abcam
(Cambridge, UK): anti-RanBP1 (ab97659), anti-p21 (EA10) and anti-CoxIV
(ab16056). Alexa-488/Alexa-568-goat-anti-mouse/rabbit (Life Technologies),
POD-goat–anti-rabbit/mouse (Jackson ImmunoResearch), FITC-p53 (DO-7, BD
Biosciences), Alexa-Fluor647-rabbit-anti-mouse/rabbit IgG(H+L) (Thermo Fisher
Scientific, Waltham, MA, USA), PE-mouse-anti-human-CD45 (HI30, BD Biosciences,
San Jose, CA, USA), PE-Cy7-anti-human-CD33 (P67.6, BD Biosciences), PE-
mouse-anti-human-CD11b (D12, BD Biosciences), Biotin-anti-CD14 (M5E2,
Biologend), Brilliant-Violet-605-anti-CD16 (3G8, Biolegend, San Diego, CA, USA),
PE-anti-CD163 (MAC2,Trillium Diagnostic), Brilliant-Violet-711-anti-CD40 (2331,
FUN-1, BD Biosciences), Pacific-Blue-anti-HLA-DR (MEM-12, EXBIO) and FITC-
anti-CD45 (MEM-28, EXBIO, Praha, Czech Republic).
The NPM1wt-ECGFP plasmid (generous gift from Professor Marikki Laiho, Johns
Hopkins University, USA) was used as template for PCR-based site-directed
mutagenesis to generate the NPMc+-ECGFP plasmid with NPM1mutantA
sequence.14 Both plasmids were verified by sequencing.
Analysis of cell viability, proliferation and cell cycle. The WST-1
(Roche, Penzberg, Germany; measured by Spectramax Plus 384 Spectro-
photometer, Molecular Devices Corporation, Sunnyvale CA, USA), resazurin (Life
Technologies), Hoechst 3334, annexinV/propidium iodide (PI) staining (Nexins
Research, Kattendijke, The Netherlands) assays and transmission electron
microscopy were performed according to the manufacturer’s protocol and as
previously described.56,57
Transfection, cytospin, immunostaining and immunoblotting.
OCI-AML3 cells were cytospun onto 12-mm coverslips using cytofunnel (400 r.p.m.,
4 min; Shandon cytospin 3) Termo Fisher Scientific, Waltham, MA, USA.
Transfection, fixation and immunostaining were performed as previously
described.58 Cells were stained by May-Grünwald (Sigma-Aldrich)-Giemsa
(Merck Milipore, Billerica, MA, USA) according to the manufacturer’s protocol.
Cells were analyzed by Zeiss Axio ObserverZ1 or Zeiss AxioVertA1 inverted
microscopes and Carl Zeiss (Oberkochen, Germany) ZEN imaging software. Final
figures were prepared using Adobe Photoshop CS5 (Adobe Systems Incorporated,
San Jose, CA, USA). Immunoblotting was performed as previously described.59 All
results are representative of at least three independent experiments.
Phagocytosis, oxidative burst and NBT reduction assays. Pha-
gocytosis and oxidative burst potential were measured in triplicates by flow
cytometry using Beckman Coulter (Brea, CA, USA) EPICS XL-MCL as described
previously.60
Briefly, Staphylococcus aureus Cowan III NCTC 8532 labeled with rhodamine
green X (Molecular Probes, Waltham, MA, USA) were used as phagocytic targets
while unlabeled bacteria were used as stimuli for oxidative burst measured with the
substrate dihydrorhodamine 123 (Fluka, Buchs, Switzerland). Bacteria were not
opsonized or opsonized with pooled human serum before both assays with PBMCs
from a healthy individual as control. For the NBT reduction assay, cells 72 h post
treatment were incubated with NBT (Sigma-Aldrich), stimulated with PMA (200 ng/ml)
for 30 min at 37 °C, cytospun, counterstained with Safranin O (Sigma-Aldrich) before
examined as described above.
Flow cytometry analysis. Cells were fixed and processed and data was
collected (FACS Calibur or Fortessa flow cytometer, BD Biosciences) and analyzed
by FlowJo software (FlowJo LLC, Ashland, OR, USA) as previously described.61 For
evaluation of myeloid differentiation cells were unfixed before staining.
Mice
BALB/c nude mice: Conducted at Shanghai SLAC (shanghai laboratory animal
center) laboratory Co. The experiments were performed according to international
standards. Female BALB/c nude mice aged 7–8 weeks (18–20 g) were ordered and
housed in specific pathogen-free conditions at ChemPartner (Shanghai, China).
Animals were held for a minimum of 3 days for acclimation before beginning of
the study.
NSG (NOD/SCID IL2rγnull) mice: The protocol for animal studies was
approved by the Norwegian State Commission for Laboratory Animals and the
experiments were performed according to the European Convention for the
Protection of Vertebrates Used for Scientific Purposes. Female NSG mice
(6–8 weeks old; Vivarium, University of Bergen) were maintained under defined
flora conditions in individually ventilated cage that was kept on a 12 h dark/night
schedule at a constant temperature of 21 °C and at 50% relative humidity. Bedding
and cages were autoclaved and changed twice per month. The mice had
continuous supply of sterile water and food, and were monitored daily by the same
personnel for the duration of the experiment.
Subcutaneous tumor models. BALB/c nude mice were injected sub-
cutaneously with suspension of 5 × 106 HTC-116 cells in serum-free medium
(0.1 ml). Animals were monitored daily by general clinical observations throughout
the study. Daily general health observation includes animal mortality, appearance,
spontaneous activity, body posture, and food and water intake.
Tumor areas (length × width) were calculated by using digital callipers throughout
the study period; tumor volumes were calculated based on the following formula:
tumor volume= ((length × width2)/2). The body weight of each mouse was measured
every day before dosing and the tumor volume was measured twice per week.
Animals showing signs of debilitations, marked body weight change with a 15% body
weight loss (compared with body weight at start of study) for three consecutive days,
or a 20% body weight loss at any time (420%) and cachexia were humanely killed.
NSG mice were injected subcutaneously with 5 × 106 OCI-AML3 cells in 0.1 ml
sterile 1 × PBS with 10% Matrigel (BD Matrigel Basement Membrane Matrix, BD
Biosciences) using a 28 G syringe. Animals were monitored closely for tumor growth;
tumor volume (mm3)= (length × width × height × 3.14159265)/6) was measured twice
weekly using digital callipers. Dosing started when tumors reached ~ 100 mm3; and
then tumors were measured every third day. Animals were monitored daily by general
clinical observations; weight (animals with410% weight loss were humanely killed),
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ruffled fur, appearance, body posture, pale extremities, food and water intake. Vehicle
control consisted of 10% DMSO in saline. When the tumors of the control animals
reached 1000 mm3 all the animals were killed.
Statistical analysis. Statistical comparisons were made using GraphPad
Prism version 5.0. (La Jolla, CA, USA) One-way analysis of variance and Tukey’s
multiple comparison post tests were used to determine significant differences
between several treatment groups. Unless otherwise stated, a Student’s unpaired t-
test was employed when only two groups were compared. IC50 values were
calculated with curve fitting non-linear regression; Pearson or Spearman correlation
determined significant dependency in Gaussian or nonparametric data, respectively.
Normality in the data sets was determined using the D’Agostino and Pearson
omnibus normality test. Data are presented as the mean ± S.E.M. of three
independent experiments in triplicate unless otherwise stated. Differences with
Po0.05 were considered statistically significant. Grubbs' method for assessing
outliers was used on the ex vivo data before data analysis.
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